The Wistar Institute Receives $1 Million From Pew Charitable Trusts for Recruitment

November 09, 1998

Philadelphia -- The Wistar Institute has received a three-year grant of $1 million from The Pew Charitable Trusts to recruit and equip the laboratories of new scientific investigators in the areas of regeneration, signal transduction and brain tumor research.

"We are having tremendous success in these areas," explained Wistar's director, Giovanni Rovera, M.D., "and we want to ensure our continued progress."

Three previous grants from the Trusts supported the recruitment of 12 new researchers that, according to Dr. Rovera, each cost the Institute roughly $700,000 during their first three years. "The Trusts' backing has transformed Wistar," he explained. These new researchers bring in innovative technologies and ideas, revitalizing existing programs and catalyzing efforts that are achieving recognition in the scientific community. We are grateful to the Trusts for laying the ground work for this initiative."

Maureen Byrnes, Director of The Pew Charitable Trusts' Health and Human Services Program, said "The Trusts have had a long and positive relationship with The Wistar Institute since 1969 and we are impressed by Wistar's continued success at recruiting such high-quality scientists."

Several Wistar scientists have also earned individual grants through the Pew Scholars Program in the Biomedical Sciences. Each year, 20 young researchers are competitively chosen to receive a $200,000 four-year grant for the scientific project of their choice. Created in 1994, the program was designed to encourage interdisciplinary research, promote medical science policy and foster breakthroughs.

The Pew Charitable Trusts, among the nation's largest philanthropies, support nonprofit activities in culture, education, the environment, health and human services, public policy and religion. Based in Philadelphia, the Trusts make strategic investments to help organizations and citizens develop practical solutions to difficult problems.

The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and location of genes that contribute to the development of diseases like breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.

The Wistar Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to